Atorvastatin-Therapie in der Praxis – LDL-Werte bei Patienten mit sehr hohem kardiovaskulären Risiko

Abstract

Current information on the utilisation of atorvastatin under clinical practice conditions is limited. The cross sectional study DISCOVER documented in the period from June until December 2014 dose and effects on lipids in ambulatory patients at very high cardiovascular risk, who were treated with atorvastatin monotherapy (original drug or generics). Of 2625 patients (mean age 66.1 ± 10.8 years, 62.1 % males), 47.0 % had coronary heart disease (CHD), 25.1 % type 2 diabetes mellitus (DM), and 27.9 % CHD plus concomitant DM. Mean treatment duration on atorvastatin was 92.6 ± 109.6 weeks, mean atorvastatin dose at time of documentation was 27.9 ± 15.8 mg/d. Low-density lipoprotein cholesterol (LDL-C) < 70 mg/dL was achieved by 10.5 % of the total cohort (7.5 % in DM, 9.3 % in CHD, and 15.2 % in CHD+DM). In contrast, according to physicians’ subjective assessment, 62.7 % of patients reached their individual LDL-C target (with small differences between groups). In conclusion, the LDL-C target level < 70 mg/dL as recommended by current guidelines is achieved only in a minority of atorvastatin treated patients at very high cardiovascular risk.

Atorvastatin wird als eines der wirksamsten zugelassenen Statine in aktuellen Leitlinien zur Sekundärprävention von Patienten mit sehr hohem und hohem kardiovaskulären Risiko empfohlen. Seit 2012 als Generikum verfügbar wird es sehr häufig in Deutschland eingesetzt. Während die Wirksamkeit und Verträglichkeit von Atorvastatin unter kontrollierten Studienbedingungen belegt wurde, sind bisher aus Deutschland keine Daten aus dem Praxisalltag verfügbar.

Key words

LDL cholesterol - atorvastatin - pharmacoepidemiology - statin - management - cardiovascular risk - treatment

• Literatur

• 1 Reiner Z, Catapano AL, De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818
• 2 Werner C, Laufs U. Moving beyond the "LDL hypothesis". Vasa 2015; 44: 333-340
• 3 Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590
• 4 Collins R, Reith C, Emberson J. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561
• 5 Fulcher J, O'Connell R, Voysey M. et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174000 participants in 27 randomised trials. Lancet 2015; 385: 1397-1405
• 6 Klose G, Schwabe U. Lipidsenkende Mittel. In: Schwabe U, Paffrath D. (Hrsg.) Arzneiverordnungs-Report 2014. Aktuelle Daten, Kosten, Trends und Kommentare. Heidelberg: Springer Verlag; 2014
• 7 Naci H, Brugts JJ, Fleurence R. et al. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol 2013; 20: 658-670
• 8 Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol 2016; 105: 783-790
• 9 Kotseva K, Wood D, De Bacquer D. et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2015; 23: 636-648
• 10 Bestehorn K, Junger C, Smolka W. et al. Regional differences in the treatment of dyslipidemia in Germany. Dtsch Med Wochenschr 2011; 136: 512-518
• 11 Gitt AK, Juenger C, Jannowitz C. et al. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil 2009; 16: 438-444
• 12 Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit Med J 2003; 326: 1423-1430
• 13 Kashani A, Phillips CO, Foody JM. et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-2797
• 14 Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med 2011; 365: 2250-2251
• 15 Zhang H, Plutzky J, Skentzos S. et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158: 526-534
• 16 Bestehorn K, Jannowitz C, Karmann B. et al. Characteristics, management and attainment of lipid target levels in patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. BMC Public Health 2009; 9: 280
• 17 Pittrow D, Stalla GK, Zeiher AM. et al. Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care. Med Klin (Munich) 2006; 101: 635-644